Enhertu approved on NHS in England to extend breast cancer survival

Enhertu, the antibody‑drug conjugate trastuzumab deruxtecan, has been prescribed in Scotland for more than two years and remains widely available through the National Health Service. Clinical studies have shown that the therapy can extend the median overall survival of patients with advanced HER2‑positive breast cancer by approximately seven months, offering a measurable increase in life expectancy for a population with limited treatment options.

The drug received approval from the UK Medicines and Healthcare products Regulatory Agency in 2021 for use in patients whose disease has progressed after prior HER2‑targeted therapies. Since its introduction, Scottish health boards have incorporated Enhertu into oncology pathways, making it accessible to eligible patients across the country. Ongoing monitoring of treatment outcomes continues to inform its role in the broader cancer care strategy, ensuring that patients benefit from the latest evidence‑based therapies.